11/21
08:38 am
itrm
Iterum Therapeutics Regains Full Nasdaq Compliance [Yahoo! Finance]
High
Report
Iterum Therapeutics Regains Full Nasdaq Compliance [Yahoo! Finance]
11/21
08:30 am
itrm
Iterum Therapeutics Regains Full Nasdaq Compliance
Medium
Report
Iterum Therapeutics Regains Full Nasdaq Compliance
11/14
07:09 am
itrm
Iterum Therapeutics Reports Third Quarter 2024 Financial Results [Yahoo! Finance]
Medium
Report
Iterum Therapeutics Reports Third Quarter 2024 Financial Results [Yahoo! Finance]
11/14
07:00 am
itrm
Iterum Therapeutics Reports Third Quarter 2024 Financial Results
Medium
Report
Iterum Therapeutics Reports Third Quarter 2024 Financial Results
11/11
08:00 am
itrm
Iterum Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024
Low
Report
Iterum Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024
10/28
05:00 am
itrm
Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections
High
Report
Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections
10/25
11:12 am
itrm
Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections [Yahoo! Finance]
High
Report
Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections [Yahoo! Finance]
10/25
11:03 am
itrm
Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections
High
Report
Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections
10/10
08:30 am
itrm
Iterum Therapeutics to Present Data at IDWeek 2024
Low
Report
Iterum Therapeutics to Present Data at IDWeek 2024
10/9
05:00 pm
itrm
Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual Summit
Medium
Report
Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual Summit